key: cord-0919146-305cpw27
authors: Nieto‐Moro, Montserrat; Ecclesia, Francesco Giuseppe; Tomé‐Masa, Irene; De Lama Caro‐Patón, Gema; Leoz‐Gordillo, Inés; Cabrero‐Hernández, Marta; García‐Salido, Alberto
title: SARS‐CoV‐2 and Streptococcus pneumoniae coinfection as a cause of severe pneumonia in an infant
date: 2020-06-29
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.24916
sha: 7a10946b8c5b018b16b7df3467f2f9ce5c4a13cf
doc_id: 919146
cord_uid: 305cpw27

nan

To the Editor, There is scarce knowledge of "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) infection in children. Its incidence appears to be lower than in adults (1%-5% of the total cases). Very few publications include severe children requiring intensive care. 1, 2 In this report, we describe the clinical course of a previously healthy infant admitted to the Pediatric Intensive Care Unit (PICU) with severe pneumonia. SARS-CoV-2 and Streptococcus pneumoniae were isolated from pleural effusion.

An 8-months-old healthy and correctly immunized male presented to the emergency department (ED). He had five-days of fever, cough, nasal congestion, and increased work of breathing over the previous hours. Chest auscultation showed hypoventilation with bilateral crackles. Oxygen therapy through nasal cannula was started, blood test including blood culture was performed and intravenous cefotaxima (200 mg/kg/d) was administered. Chest X-ray (CXR) revealed a left lower lobe (LLL) opacity and small pleural effusion ( Figure 1 ).

Laboratory findings showed increased levels of C-reactive protein (CRP), procalcitonin (PCT), ferritin, and interleukin-6 (IL-6; Table 1 ).

Reverse transcription-polymerase chain reaction (RT-PCR) on nasopharyngeal swab (NPS) for SARS-CoV-2 revealed positive. His clinical condition deteriorated, he was transferred to the PICU. On admission, high flow nasal cannula (HFNC) oxygen therapy was initiated. There was no improvement so noninvasive ventilation (NIV) was started.

Empirical drugs for coronavirus disease-2019 (COVID-19) were initiated (azithromycin 10 mg/kg/d, lopinavir/ritonavir 12/3 mg/kg/12 h, and hydroxychloroquine 6.5 mg/kg/12 h).

Forty-eight hours later, he became apyretic with improved laboratory tests. However, he remained oxygen dependent on NIV.

Blood culture taken in the ED was positive for S. pneumoniae. Table 1 . Also, new blood cultures were done to discard other bacteria or coinfections. Methylprednisolone and hydroxychloroquine were reinitiated. Antibiotic therapy was switched to intravenous meropenem (20 mg/kg/d/8 h) and linezolid (10 mg/kg/12 h) to broaden the antibiotic spectrum.

The patient improved during the next days. He was discharged to the pediatric ward again after 5 days in PICU. His chest ultrasound and bloodwork kept improving (Table 1) . He received steroids for 14 days. He was discharged home after 18 days. At home, he con- the therapy for bacterial pneumonia due to the potential immunosuppressant effect. However, they could play a role in severe COVID-19. The cytokines profile has been described similar to secondary hemophagocytic lymphohistiocytosis. 4 In regard to these findings along with the increased inflammatory markers in our case (Table 1) , methylprednisolone was used. The steroids could treat the immune dysregulation produced by this virus. The efficacy of the empirical treatment given for COVID-19 (azithromycin, lopinavir/ ritonavir, and hydroxychloroquine) is uncertain.

In summary, we describe a severe case of SARS-CoV-2 and S. 

Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children

Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10

Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China

Retrospective study in children with necrotizing pneumonia: nine years of intensive care experience